Article Page

Abstract

This paper deals with the some oscillation criteria for the two-dimensional neutral delay difference system of the form Examples of Oscillation and Asymptotic Behaviour of Solutions of Nonlinear Two-Dimensional Neutral Delay Difference Systems of aromatic interactions in amyloidosis via aliphatic LD6(LAGD), ID3(IVD) and KE7(KLVFFAE) peptides, as a novel Experimental simulation of quantum tunneling in small GA-biophoric scaffolds for the generation of similar self-assembly chemico-lead molecules to amyloid core sequences illustrating the results are inserted

Keywords

Asymptotic, Two-Dimensional Neutral Delay Difference Systems;Oscillation and Asymptotic Behaviour of Solutions; Nonlinear; Two-Dimensional; Neutral Delay; Difference Systems; aromatic interactions; amyloidosis; aliphatic; LD6(LAGD), ID3(IVD) and KE7(KLVFFAE) peptides, Experimental simulation; quantum tunneling; small GA-biophoric; scaffolds; self-assembly; chemico-lead; molecules; amyloid core sequences;

Article Type

Research Article – Abstract

Publication history

Received: Sep 20, 2017
Accepted: Sep 25, 2017
Published: Oct 01, 2017

Citation

Grigoriadis Ioannis, Grigoriadis George, Grigoriadis Nikolaos, George Galazios (2017) Oscillation and Asymptotic Behaviour of Solutions of Nonlinear Two-Dimensional Neutral Delay Difference Systems of aromatic interactions in amyloidosis via aliphatic LD6(LAGD), ID3(IVD) and KE7(KLVFFAE) peptides, as a novel Experimental simulation of quantum tunneling in small GA-biophoric scaffolds for the generation of similar self-assembly chemico-lead molecules to amyloid core sequences.

Authors Info

Grigoriadis Nikolaos
Department of IT Computer Aided Personalized Myoncotherapy, Cartigenea-Cardiogenea, Neurogenea-Cellgenea, Cordigenea-HyperoligandorolTM,
Biogenea Pharmaceuticals Ltd,
Thessaloniki, Greece;

Grigoriadis Ioannis
Department of Computer Drug Discovery Science, BiogenetoligandorolTM,
Biogenea Pharmaceuticals Ltd,
Thessaloniki, Greece;

Grigoriadis George
Department of Stem Cell Bank and ViroGeneaTM,
Biogenea Pharmaceuticals Ltd,
Thessaloniki, Greece;

George Galazios
Professor of Obstetrics and Gynecology,
Democritus University of Thrace,
Komotini, Greece;

E-mail: biogeneadrug@gmail.com

File not available